INTECH Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

INTECH Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$687K	Sell	26,209 -4,844	-16%	-$113K	0.01%	1197
2026 Q1	$732K	Sell	31,053 -19,557	-39%	-$499K	0.01%	1157
2025 Q4	$1.47M	Hold	50,610	–	–	0.01%	908
2025 Q3	$954K	Sell	50,610 -35,672	-41%	-$563K	0.01%	1194
2025 Q2	$1.21M	Buy	86,282 +16,588	+24%	+$233K	0.01%	1087
2025 Q1	$1.09M	Buy	69,694 +27,436	+65%	+$387K	0.01%	1143
2024 Q4	$589K	Buy	42,258 +5,168	+14%	+$56.6K	0.01%	1460
2024 Q3	$345K	Buy	+37,090	New	+$366K	﹤0.01%	1436

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

INTECH Investment Management's ARQT Position: Q2 2026 in Review

INTECH Investment Management reduced its Arcutis Biotherapeutics (ARQT) stake by 16% in Q2 2026, selling an estimated $113K and leaving 26,209 shares worth $687K. The position accounts for 0.01% of the portfolio, ranked #1197.

INTECH Investment Management first reported a position in ARQT in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.47M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

INTECH Investment Management held 26,209 shares of Arcutis Biotherapeutics worth $687K as of Q2 2026.
INTECH Investment Management sold 4,844 Arcutis Biotherapeutics shares in Q2 2026, an estimated $113K.
Arcutis Biotherapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1197 holding.
INTECH Investment Management first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Arcutis Biotherapeutics position peaked at $1.47M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.